| abstract |
The present invention relates to the drug 4'-cyano-α ', α', α'-trifluoro-3- (4-fluorophenylsulfonyl)-in a solid dispersion comprising an enteric polymer having a pKa of 3-6. A pharmaceutical formulation comprising 2-hydroxy-2-methylpropiono-m-toluidide, wherein> 50% of the drug is provided in the R enantiomer. The invention further relates to the daily pharmaceutical dosage of the drug provided by such a formulation. In addition, the present invention provides a method for increasing the bioavailability of a drug; for reducing inter-patient variability of plasma concentrations of the drug; for increasing the storage stability of the drug; or for prostate cancer in a patient. for reducing the risk of and / or prostate cancer to treat, with the use of enteric polymers having 3-6 pK a of a solid dispersion comprising the drug, wherein> 50% For the use wherein the drug is given in the form of the R enantiomer. |